Insider buying in a small pharmaceutical company, Infinity Pharmaceuticals. The CEO has been increasing her position in the stock. Warning: this is a very illiquid stock! – Ilene
Here’s an excerpt from Sabrient’s ratings report on INFI:
Infinity Pharmaceuticals, Inc. engages in the discovery and development of medicines for the treatment of cancer and related conditions in the United States.
Earnings and Revenue Update: For the quarter ended June 30, 2010, Infinity reported earnings of $-6.2 million or $-0.24 per share compared with $-8.4 million or $-0.32 per share for the prior quarter and $-11.3 million or $-0.43 per share for the same quarter one year ago. Revenues were $18.4 million for the quarter ended June 30, 2010 compared with $16.0 million for the prior quarter and $13.2 million for the same quarter one year ago. Last twelve months’ earnings were $-1.22 per share compared with $0.89 per share a year ago. Last twelve months’ revenues were $61.3 million compared with $92.1 million a year ago.
Sabrient Analysis
Although INFI has an impressive growth score, the stock is rated a Hold because it lacks the most compelling combination of attributes being rewarded in today’s market.
• Growth: A Sabrient Growth Score of 89.5 places INFI in the upper ranges of the Sabrient composite measure for growth potential. Such a score points toward favorable current EPS trends.
• Value: The stock is likely to be considered fully valued or possibly overvalued based on its Sabrient Value Score of 25.1.
• Momentum: INFI receives a Sabrient Momentum Score of 15.3, which puts it among the lowest Sabrient momentum rankings. The score is a composite measure of price, earnings and group momentum.
• Timeliness: INFI has a Sabrient Timeliness Score of 40.9. This measures technical strength based on short-term and long-term price performance and long-term group strength.
